Variable Response to ALK Inhibitors in NSCLC With a Novel MYT1L-ALK Fusion

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.169
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Carcinoma of Unknown Primary With EML4‐ALK Fusion Response to ALK Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Dramatic Response to Alectinib in a Lung Cancer Patient With a Novel VKORC1L1-ALK Fusion and an Acquired ALK T1151K Mutation

Lung Cancer: Targets and Therapy
Oncology
2018English

P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ALK (D5F3) CDx: An Immunohistochemistry Assay to Identify ALK-positive NSCLC Patients

Pharmacogenomics and Personalized Medicine
Molecular MedicinePharmacology
2018English

SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

Brigatinib Bei ALK-positivem NSCLC

Im Focus Onkologie
2017English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy